February 21, 2019
Novartis Pharma’s Kymriah (tisagenlecleucel) cleared a key health ministry panel on February 20, opening the way for its approval as Japan’s first CAR-T cell therapy as early as March. With its arrival on the horizon, all eyes are now riveted...read more